Brunel University Research Archive(BURA) preserves and enables easy and open access to all
types of digital content. It showcases Brunel's research outputs.
Research contained within BURA is open access, although some publications may be subject
to publisher imposed embargoes. All awarded PhD theses are also archived on BURA.
Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/25335Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Manca, R | - |
| dc.contributor.author | Valera-Bermejo, JM | - |
| dc.contributor.author | Venneri, A | - |
| dc.contributor.other | Alzheimer’s Disease Neuroimaging Initiative | - |
| dc.date.accessioned | 2022-10-19T11:07:40Z | - |
| dc.date.available | 2022-10-19T11:07:40Z | - |
| dc.date.issued | 2022-05-13 | - |
| dc.identifier | ORCID iDs: Riccardo Manca https://orcid.org/0000-0003-1715-6442; Annalena Venneri https://orcid.org/0000-0002-9488-2301. | - |
| dc.identifier.citation | Manca, R., Valera-Bermejo, J.M. and Venneri, A. for the Alzheimer’s Disease Neuroimaging Initiative (2022) 'Accelerated atrophy in dopaminergic targets and medial temporo-parietal regions precedes the onset of delusions in patients with Alzheimer’s disease, European Archives of Psychiatry and Clinical Neuroscience, 273 (1), pp. 229 - 241. doi: 10.1007/s00406-022-01417-5. | en_US |
| dc.identifier.issn | 0940-1334 | - |
| dc.identifier.uri | https://bura.brunel.ac.uk/handle/2438/25335 | - |
| dc.description | Additional information: *Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf. | en_US |
| dc.description | Supplementary Information: Below is the link to the electronic supplementary material. Supplementary file1 available at https://static-content.springer.com/esm/art%3A10.1007%2Fs00406-022-01417-5/MediaObjects/406_2022_1417_MOESM1_ESM.docx (DOCX 21 KB). | - |
| dc.description.abstract | Copyright © 2022 The Author(s). People with Alzheimer’s disease (AD) and delusions have worse quality of life and prognosis. However, early markers of delusions have not been identified yet. The present study investigated whether there are any detectable differences in grey matter (GM) volume and cognitive changes in the year before symptom onset between patients with AD who did and did not develop delusions. Two matched samples of AD patients, 63 who did (PT-D) and 63 who did not develop delusions (PT-ND) over 1 year, were identified from the Alzheimer’s Disease Neuroimaging Initiative database. The Neuropsychiatric Inventory (NPI) was used to assess the presence of delusions. Sixty-three additional matched healthy controls (HC) were selected. Repeated-measures ANCOVA models were used to investigate group-by-time effects on the volume of selected GM regions of interest and on cognitive performance. No neurocognitive differences were observed between patient groups prior to symptom onset. Greater episodic memory decline and GM loss in bilateral caudate nuclei, medio-temporal and midline cingulo-parietal regions were found in the PT-D compared with the PT-ND group. A pattern of faster GM loss in brain areas typically affected by AD and in cortical and subcortical targets of dopaminergic pathways, paralleled by worsening of episodic memory and behavioural symptoms, may explain the emergence of delusions in patients with AD. | en_US |
| dc.description.sponsorship | Not applicable. Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson and Johnson Pharmaceutical Research and Development LLC.; Lumosity; Lundbeck; Merck and Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. RM is supported by a Brunel University London research fellowship. JMVB is funded by a scholarship by the Consejo Nacional de Ciencia y Tecnología (CONACYT), Mexico. | en_US |
| dc.format.extent | 229 - 241 | - |
| dc.format.medium | Print-Electronic | - |
| dc.language | English | - |
| dc.language.iso | en_US | en_US |
| dc.publisher | Springer Nature | en_US |
| dc.rights | Copyright © 2022 The Author(s). Rights and permissions: Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/. | - |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | - |
| dc.subject | Alzheimer | en_US |
| dc.subject | delusions | en_US |
| dc.subject | dopamine | en_US |
| dc.subject | nigro-striatal | en_US |
| dc.subject | MRI | en_US |
| dc.subject | atrophy | en_US |
| dc.title | Accelerated atrophy in dopaminergic targets and medial temporo-parietal regions precedes the onset of delusions in patients with Alzheimer’s disease | en_US |
| dc.type | Article | en_US |
| dc.identifier.doi | https://doi.org/10.1007/s00406-022-01417-5 | - |
| dc.relation.isPartOf | European Archives of Psychiatry and Clinical Neuroscience | - |
| pubs.issue | in press | - |
| pubs.issue | 1 | - |
| pubs.publication-status | Published | - |
| pubs.volume | 273 | - |
| dc.identifier.eissn | 1433-8491 | - |
| dc.rights.holder | The Author(s) | - |
| Appears in Collections: | Dept of Life Sciences Research Papers | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| FullText.pdf | Copyright © 2022 The Author(s). Rights and permissions: Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/. | 868.04 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License
